

Peter B Berger

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11922274/peter-b-berger-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224 papers	25,445 citations	73 h-index	157 g-index
240 ext. papers	28,305 ext. citations	9 avg, IF	6.14 L-index

#	Paper	IF	Citations
224	Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2411-20	27.4	2289
223	Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. <i>New England Journal of Medicine</i> , 2006 , 354, 1706-17	59.2	2120
222	Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. <i>Circulation</i> , 2002 , 105, 2259-64	16.7	1275
221	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1097-105	27.4	959
220	Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1982-8	15.1	638
219	Variability in platelet responsiveness to clopidogrel among 544 individuals. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 246-51	15.1	630
218	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 299S-339S	5.3	621
217	The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1113-9	15.1	575
216	Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1531-8	27.4	561
215	Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. <i>New England Journal of Medicine</i> , 2005 , 353, 46-57	59.2	545
214	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Circulation</i> , 2002 , 105, 1257-1267	15.1	507
213	ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Circulation</i> , 2002 , 105, 1257-1267	16.7	496
212	A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. <i>New England Journal of Medicine</i> , 2004 , 350, 232-8	59.2	481
211	Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. <i>Circulation</i> , 1999 , 100, 14-20	16.7	462
210	Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2096-104	27.4	412
209	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013 , 382, 1714-22	40.2	405
208	Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 690-7	15.1	381

207	Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 234-40	15.1	366
206	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. <i>Circulation</i> , 2011 , 124, 1132-7	16.7	331
205	Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. <i>Circulation</i> , 2001 , 103, 2572-8	16.7	323
204	Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 668-74	15.1	300
203	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. <i>New England Journal of Medicine</i> , 2008 , 359, 688-96	59.2	287
202	Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. <i>American Journal of Cardiology</i> , 2005 , 95, 1218-22	3	267
201	Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2371-80	27.4	258
200	Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 9-14	15.1	249
199	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2011 , 365, 1980-9	59.2	230
198	Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. <i>Circulation</i> , 2003 , 108, 921-4	16.7	216
197	Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. <i>European Heart Journal</i> , 2005 , 26, 137-44	9.5	199
196	The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 776S-814S	5.3	196
195	Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , 2005 , 111, 940-53	16.7	187
194	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. <i>Journal of Lipid Research</i> , 2007 , 48, 425-33	6.3	178
193	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>Circulation</i> , 2010 , 121, 2575-83	16.7	173
192	Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. <i>Circulation</i> , 1999 , 100, 2067-73	16.7	173
191	Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. <i>American Heart Journal</i> , 2004 , 147, 463-7	4.9	163
190	ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). <i>Circulation</i> , 2002 , 105, 1257-67	16.7	161

189	Perioperative management of patients with coronary stents. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2145-50	15.1	157
188	Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 572-84	7	152
187	Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 939-43	15.1	145
186	The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2008 , 155, 687-93	4.9	144
185	Cardiogenic shock complicating acute coronary syndromes. <i>Lancet, The</i> , 2000 , 356, 749-56	4.0	144
184	Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. <i>Circulation</i> , 1997 , 96, 122-7	16.7	139
183	Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. <i>Circulation</i> , 2000 , 101, 2795-802	16.7	136
182	A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. <i>Circulation</i> , 1995 , 91, 1966-74	16.7	134
181	Clopidogrel versus ticlopidine after intracoronary stent placement. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1891-4	15.1	132
180	Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. <i>Annals of Internal Medicine</i> , 2009 , 150, 379-86	8	126
179	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 2133-6	15.1	125
178	Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1567-72	15.1	120
177	Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. <i>Archives of Internal Medicine</i> , 2004 , 164, 2051-7		118
176	Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 920-7	5	111
175	Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. <i>Circulation</i> , 2009 , 120, 2337-44	16.7	110
174	The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1935-45	15.1	103
173	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 2168-73	15.1	98
172	Plasma Ceramides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018 , 38, 1933-1939	9.4	97

171	Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 8-14	5.8	95
170	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009 , 157, 818-24, 824.e1	4.9	92
169	Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. <i>American Journal of Cardiology</i> , 1993 , 71, 1148-52	3	92
168	Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1752-8	15.1	91
167	Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). <i>American Journal of Cardiology</i> , 2009 , 103, 1359-63	3	90
166	Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). <i>American Journal of Cardiology</i> , 2001 , 88, 1091-6	3	90
165	Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. <i>Journal of the American College of Cardiology</i> , 1992 , 20, 533-40	15.1	89
164	Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1724-34	15.1	88
163	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 522-34	6	88
162	Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1188-95	15.1	88
161	Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 423-8	5.8	86
160	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. <i>American Heart Journal</i> , 2007 , 154, 3-11	4.9	86
159	Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. <i>Circulation</i> , 1999 , 99, 248-53	16.7	86
158	Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. <i>Lancet, The</i> , 1997 , 349, 75-8	4.0	81
157	Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. <i>American Heart Journal</i> , 2004 , 147, 815-22	4.9	80
156	Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 272-9	15.1	75
155	One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. <i>Circulation</i> , 1999 , 99, 873-8	16.7	75
154	Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. <i>American Journal of Cardiology</i> , 2005 , 96, 512-4	3	74

153	Intercenter variability in outcome for patients treated with direct coronary angioplasty during acute myocardial infarction. <i>American Heart Journal</i> , 1998 , 135, 310-7	4.9	74
152	Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. <i>American Journal of Cardiology</i> , 1999 , 83, 1006-11	3	74
151	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012 , 33, 2143-50	9.5	73
150	Referral for coronary artery revascularization procedures after diagnostic coronary angiography: evidence for gender bias?. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1650-5	15.1	73
149	Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. <i>Archives of Internal Medicine</i> , 2008 , 168, 94-102		68
148	Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1448-58	15.1	68
147	Management of patients undergoing percutaneous coronary revascularization. <i>Annals of Internal Medicine</i> , 2003 , 139, 123-36	8	66
146	Clinical safety of magnetic resonance imaging early after coronary artery stent placement. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1295-8	15.1	65
145	Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2. <i>Circulation</i> , 2018 , 137, 376-387	16.7	65
144	Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>American Heart Journal</i> , 2009 , 157, 369-74	4.9	63
143	Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. <i>American Journal of Medicine</i> , 2000 , 108, 187-92	2.4	63
142	Frequency of early occlusion and stenosis in a left internal mammary artery to left anterior descending artery bypass graft after surgery through a median sternotomy on conventional bypass: benchmark for minimally invasive direct coronary artery bypass. <i>Circulation</i> , 1999 , 100, 2353-8	16.7	63
141	Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. <i>Circulation</i> , 2016 , 134, 365-74	16.7	63
140	Long-term outcome of women compared with men after successful coronary angioplasty. <i>Circulation</i> , 1995 , 91, 2876-81	16.7	60
139	Cardiovascular disease and chronic kidney disease: insights and an update. <i>American Heart Journal</i> , 2004 , 148, 230-42	4.9	58
138	Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1786-1791	15.1	56
137	Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). <i>American Heart Journal</i> , 2001 , 142, 301-8	4.9	56
136	Balloon angioplasty of chronic total coronary artery occlusions: what does it cost in radiation exposure, time, and materials?. <i>Catheterization and Cardiovascular Diagnosis</i> , 1992 , 25, 10-5		56

135	Outcome > or = 10 years after successful percutaneous transluminal coronary angioplasty. <i>American Journal of Cardiology</i> , 1997 , 79, 1005-11	3	53
134	Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. <i>Circulation</i> , 2008 , 118, 632-8	16.7	53
133	Renal function, concomitant medication use and outcomes following acute coronary syndromes. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 2105-12	4.3	53
132	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. <i>European Heart Journal</i> , 2010 , 31, 582-7	9.5	48
131	Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. <i>American Journal of Cardiology</i> , 2001 , 87, 630-3, A9	3	48
130	An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery. <i>American Journal of Cardiology</i> , 2001 , 87, 1100-2, A6, A9	3	48
129	Application of the New York State PTCA mortality model in patients undergoing stent implantation. <i>Circulation</i> , 2000 , 102, 517-22	16.7	48
128	Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 361-7	15.1	48
127	Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). <i>Journal of the American College of Cardiology</i> , 1996 , 27, 1-7	15.1	47
126	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. <i>American Heart Journal</i> , 2001 , 142, 452-9	4.9	46
125	Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2717-26	15.1	45
124	Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. <i>Atherosclerosis</i> , 2003 , 168, 315-22	3.1	45
123	Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 354-61	6	44
122	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2009 , 30, 290-6	9.5	44
121	The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. <i>American Heart Journal</i> , 2005 , 149, 869-75	4.9	44
120	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>European Heart Journal</i> , 2008 , 29, 455-61	9.5	43
119	In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 349-54	3	42
118	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. <i>European Heart Journal</i> , 2005 , 26, 1379-84	9.5	41

117	Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. <i>American Heart Journal</i> , 2003 , 146, 345-50	4.9	41
116	Readmission in the 30 days after percutaneous coronary intervention. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 237-44	5	39
115	Predictors of reperfusion delay in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention from the HORIZONS-AMI trial. <i>American Journal of Cardiology</i> , 2010 , 106, 1527-33	3	39
114	Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). <i>American Journal of Cardiology</i> , 2006 , 98, 1172-6	3	39
113	Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. <i>American Heart Journal</i> , 2001 , 141, 47-54	4.9	39
112	Time to reperfusion with direct coronary angioplasty and thrombolytic therapy in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1994 , 73, 231-6	3	39
111	Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?. <i>European Heart Journal</i> , 2016 , 37, 1284-95	9.5	38
110	Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. <i>American Heart Journal</i> , 2009 , 157, 651-7	4.9	38
109	Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. <i>Circulation</i> , 2002 , 106, 2284-7	16.7	38
108	Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts. <i>American Journal of Cardiology</i> , 1992 , 70, 449-54	3	37
107	Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003586	6	36
106	Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. <i>Journal of the American Heart Association</i> , 2013 , 2, e004564	6	35
105	Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). <i>Circulation</i> , 2003 , 107, 2331-6	16.7	35
104	Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1036-46	5	35
103	Cardiogenic shock--Beyond the large infarction. <i>Critical Care Medicine</i> , 2006 , 34, 2234-5	1.4	34
102	A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1608-13	15.1	34
101	Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. <i>American Heart Journal</i> , 2004 , 147, 1066-70	4.9	33
100	Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. <i>American Heart Journal</i> , 2002 , 143, 811-6	4.9	33

99	Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2011 , 162, 98-105.e1	4.9	32
98	Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. <i>Circulation</i> , 2006 , 114, 2040-6	16.7	32
97	Allergic reactions to clopidogrel and cross-reactivity to other agents. <i>Current Allergy and Asthma Reports</i> , 2011 , 11, 52-7	5.6	31
96	Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2007 , 40, 265-70	1.4	31
95	Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. <i>American Journal of Cardiology</i> , 2004 , 94, 623-5	3	30
94	Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). <i>American Journal of Cardiology</i> , 2003 , 92, 330-3	3	29
93	Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. <i>Journal of Thrombosis and Thrombolysis</i> , 2005 , 19, 11-9	5.1	29
92	Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisal. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1881-9	15.1	28
91	Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. <i>Circulation: Cardiovascular Interventions</i> , 2009 , 2, 348-51 ⁶	4.9	27
90	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2005 , 150, 401	4.9	27
89	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2015 , 11, 196-203	3.1	27
88	Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 77-81	6	26
87	Clinical outcome of patients undergoing endoluminal coronary artery reconstruction with three or more stents. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 676-81	15.1	25
86	Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). <i>American Journal of Cardiology</i> , 2007 , 99, 349-52	3	24
85	Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets: what's behind this new lexicon and what does it add?. <i>Circulation</i> , 2001 , 104, 627-9	16.7	24
84	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	23
83	Improving outcome over time of percutaneous coronary interventions in unstable angina. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 674-8	15.1	23
82	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1824-1833 ²³	5.1	23

81	Comparison of intermediate-term outcomes of coronary artery bypass grafting versus drug-eluting stents for patients ≥5 years of age. <i>American Journal of Cardiology</i> , 2014 , 113, 803-8	3	22
80	Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. <i>American Journal of Cardiology</i> , 2010 , 105, 163-7	3	22
79	Changes in Percutaneous Coronary Interventions Deemed "Inappropriate" by Appropriate Use Criteria. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1234-1242	15.1	21
78	Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. <i>Circulation: Cardiovascular Interventions</i> , 2009 , 2, 503-12	6	21
77	Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. <i>Cerebrovascular Diseases</i> , 2008 , 25, 344-7	3.2	20
76	The thienopyridines. <i>Journal of Interventional Cardiology</i> , 2002 , 15, 85-93	1.8	20
75	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. <i>American Heart Journal</i> , 2007 , 154, 158.e1-7	4.9	19
74	Hemorrhagic and Vascular Complications After Percutaneous Coronary Intervention With Adjunctive Abciximab. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 890-896	6.4	19
73	Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 1732-7	15.1	19
72	Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. <i>American Journal of Cardiology</i> , 1995 , 76, 565-9	3	19
71	Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization. <i>JAMA Cardiology</i> , 2018 , 3, 123-130	16.2	18
70	Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. <i>American Heart Journal</i> , 2014 , 168, 537-44	4.9	18
69	Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. <i>American Heart Journal</i> , 2011 , 161, 360-6	4.9	18
68	Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1786-91	15.1	18
67	Percutaneous Coronary Intervention for ST-Segment and Non-ST-Segment Elevation Myocardial Infarction at Hospitals With and Without On-site Cardiac Surgical Capability. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 738-744	6.4	18
66	Effectiveness and safety of abciximab after failed thrombolytic therapy. <i>American Journal of Cardiology</i> , 2001 , 87, 439-42, A4	3	18
65	Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?. <i>Journal of Interventional Cardiology</i> , 2015 , 28, 223-32	1.8	17
64	Impact of pre-hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST-segment elevation myocardial infarction network. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 245-251	2.7	15

63	Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2017 , 227, 808-812	3.2	15
62	Interventional cardiology and intracoronary stents--a changing practice: approved vs. nonapproved indications. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997 , 40, 133-8		15
61	The risk of drug-eluting stent thrombosis with noncardiac surgery. <i>Current Cardiology Reports</i> , 2007 , 9, 406-11	4.2	15
60	Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 301-7	6.4	15
59	Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?. <i>Circulation</i> , 2004 , 109, 1079-81	16.7	15
58	Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?. <i>Catheterization and Cardiovascular Interventions</i> , 2008 , 72, 815-8	2.7	14
57	Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals. <i>Pharmacotherapy</i> , 2006 , 26, 1537-56	5.8	14
56	Frequency of coronary angiography and revascularization among men and women with myocardial infarction and their relationship to mortality at one year: an analysis of the Geisinger myocardial infarction cohort. <i>Journal of Interventional Cardiology</i> , 2013 , 26, 14-21	1.8	13
55	Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000 , 1, 83-87		13
54	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 190-198	2.7	12
53	Paroxysmal atrial fibrillation and the hazards of under-treatment. <i>International Journal of Cardiology</i> , 2016 , 202, 214-20	3.2	12
52	Utilization of radial artery access for percutaneous coronary intervention for ST-segment elevation myocardial infarction in New York. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 276-83	5	12
51	Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. <i>Atherosclerosis</i> , 2002 , 165, 375-81	3.1	12
50	The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. <i>Urology</i> , 2013 , 82, 773-9	1.6	11
49	Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 742-50	5	11
48	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , 2008 , 97, 160-8	6.1	11
47	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	10
46	Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001712	6	10

45	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2007 , 82, 301-307	6.4	10
44	The thienopyridines in coronary artery disease. <i>Current Cardiology Reports</i> , 1999 , 1, 192-8	4.2	10
43	Management of balloon rupture during rigid stent deployment. <i>Catheterization and Cardiovascular Diagnosis</i> , 1995 , 35, 211-5		10
42	Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. <i>Clinical Cardiology</i> , 2008 , 31, 12-9	3.3	9
41	Bleeding is bad.... isn't it?. <i>Circulation</i> , 2007 , 116, 2776-8	16.7	9
40	Is the heat on HEAT-PPCI appropriate?. <i>Lancet, The</i> , 2014 , 384, 1824-1826	4.0	8
39	The glycoprotein IIb/IIIa inhibitor wars: an update. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 476-8	15.1	8
38	Noninvasive prediction of residual blood flow within the risk area during acute myocardial infarction: a multicenter validation study of patients undergoing direct coronary angioplasty. <i>American Heart Journal</i> , 1997 , 134, 639-46	4.9	8
37	Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 8-13	5.1	8
36	Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. <i>Mayo Clinic Proceedings</i> , 2001 , 76, 890-6	6.4	8
35	Use of excimer laser in the treatment of chronic total occlusion of a coronary artery that cannot be crossed with a balloon catheter. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993 , 28, 44-6		8
34	Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). <i>American Journal of Cardiology</i> , 2009 , 104, 1285-91	3	7
33	Investigating the mechanisms of hyporesponse to antiplatelet approaches. <i>Clinical Cardiology</i> , 2008 , 31, 121-7	3.3	7
32	Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. <i>American Heart Journal</i> , 2005 , 150, 796-9	4.9	7
31	Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. <i>Journal of Invasive Cardiology</i> , 2009 , 21, 194-200	0.7	7
30	ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. <i>American Heart Journal</i> , 2009 , 158, 400-7	4.9	5
29	Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). <i>American Heart Journal</i> , 2001 , 142, 776-81	4.9	5
28	Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction. <i>International Journal of Cardiology</i> , 1993 , 38, 151-8	3.2	5

27	Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics. <i>American Heart Journal</i> , 2017 , 186, 118-126	4.9	4
26	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , 2015 , 170, 706-14	4.9	4
25	Sex differences in the treatment and outcomes of patients hospitalized with ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 196-204	2.7	4
24	Therapeutic goals for effective platelet inhibition: a consensus document. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 214-25	3.9	4
23	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , 2011 , 100, 579-85	6.1	3
22	Intracoronary glycoprotein IIb/IIIa inhibitors from questioning the logic to weighing the data. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 935-6	5	3
21	Resistance to antiplatelet drugs: is it real or relevant?. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 62, 43-5	2.7	3
20	Appending Limited Clinical Data to an Administrative Database for Acute Myocardial Infarction Patients: The Impact on the Assessment of Hospital Quality. <i>Medical Care</i> , 2016 , 54, 538-45	3.1	3
19	Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction. <i>Journal of Interventional Cardiology</i> , 2013 , 26, 623-9	1.8	2
18	Can percutaneous coronary interventions reduce death and myocardial infarction in stable and unstable coronary disease?. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 61, 528-36	2.7	2
17	Immediate and one-year outcome of intracoronary stent implantation in small coronary arteries with 2.5-mm stents. <i>American Heart Journal</i> , 2000 , 140, 898-905	4.9	2
16	Impact of stent size and indication for stent placement on immediate outcome. <i>Catheterization and Cardiovascular Diagnosis</i> , 1996 , 38, 145-51		2
15	Cyclosporine for Reperfusion Injury After Cardiac Arrest: Too Little Too Late?. <i>JAMA Cardiology</i> , 2016 , 1, 566-7	16.2	1
14	P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?. <i>Current Cardiology Reports</i> , 2011 , 13, 320-6	4.2	1
13	Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 284-7; discussion 288	6	1
12	Response to Letters Regarding Article, Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. <i>Circulation</i> , 2012 , 125,	16.7	1
11	Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 128-35	3.3	1
10	Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 17, 11-20	5.1	1

9	Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 18, 25-30	5.1	1
8			
7	Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007097	6	0
6	Reply: Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1716	15.1	
5	Pharmacology of Intravenous Glycoprotein IIb/IIIa Antagonists95-110		
4	Transport and centralization of acute coronary syndrome care. <i>Current Cardiology Reports</i> , 2004 , 6, 292-94.2		
3	Enoxaparin may reduce the risk of myocardial infarction among people at increased risk of stent thrombosis, but is unnecessary for most people. <i>Evidence-based Cardiovascular Medicine</i> , 2002 , 6, 137-138		
2	Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis. <i>Circulation</i> , 2000 , 101, E211-2	16.7	
1	Review: Early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. <i>ACP Journal Club</i> , 2006 , 145, 61		